Fig. 2: Association of BCR and TCR measures with EFS in the NeoALTTO and CALGB 40601 cohorts. | Nature Communications

Fig. 2: Association of BCR and TCR measures with EFS in the NeoALTTO and CALGB 40601 cohorts.

From: Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Fig. 2

a Forest plot for EFS in the NeoALTTO cohort, univariable analysis. b Forest plot for EFS in the CALGB 40601 cohort, univariable analysis. c Forest plot for EFS in the NeoALTTO cohort, correcting for clinicopathological parameters (age, hormone receptor status, tumor size, nodal status, PAM50 subtypes, and treatment arm). d Forest plot for EFS in the CALGB 40601 cohort, correcting for clinicopathological parameters (age, hormone receptor status, tumor size, nodal status, PAM50 subtypes, and treatment arm). For univariable analysis, P values are from likelihood ratio test. When correcting for clinicopathological characteristics, P values were obtained with an ANOVA on nested Cox models. P values are two-sided. Non-significant values (FDR > 0.05) are shown in dark gray, significant values are shown in red (HR > 1) and blue (HR < 1). Circles indicate HR, and error bars the 95% confidence interval (95% CI). Analyses were performed including patients with available data. In NeoALTTO, N = 254 for all BCR/TCR metrics, except TCR CDR3 length, TCR Gini, TCR Gini-Simpson, TCR top clone (N = 253) and TCR evenness, TCR second top clone (N = 251). In CALGB 40601, for all BCR/TCR measures N = 264 in univariable, N = 248 in multivariable. 95% CI 95% confidence interval, BCR B cell receptor, CDR3 complementarity-determining region 3, EFS event-free survival, FDR false discovery rate, HR hazard ratio, N reads number of normalized reads, N clones number of clones, TCR T cell receptor.

Back to article page